Soluble CD14: an independent biomarker for the risk of mother-to-child transmission of HIV in a setting of preexposure and postexposure antiretroviral prophylaxis

Citation: Shivakoti R, Gupta A, Ray JC, Uprety P, Gupte N, Bhosale R, Mave V, Patil S, Balasubramanian U, Kinikar A, Bharadwaj R, Bollinger RC, Persaud D. Soluble CD14: an independent biomarker for the risk of mother-to-child transmission of HIV in a setting of preexposure and postexposure antiretroviral prophylaxis. J Infect Dis. 2016 Mar 1;213(5):762-5. doi: 10.1093/infdis/jiv479. Epub 2015 Oct 6. PMID: 26443598. PMCID: PMC4747613  

Access full article:

http://www.ncbi.nlm.nih.gov/pubmed/26443598

Elevated soluble CD14 (sCD14) concentrations, a marker of monocyte activation, predicts adverse outcomes in human immunodeficiency virus (HIV)-infected adults. To examine the association of sCD14 concentrations with the risk of mother-to-child transmission (MTCT) of HIV, we nested a case-control study (49 pairs of infants and their HIV-infected mothers) within the Six-Week Extended-Dose Nevirapine trial. Median peripartum maternal log2 sCD14 concentration was higher among transmitters (defined as pairs in which maternally transmitted HIV infection occurred by 12 months of age) than nontransmitters (20.29 pg/mL vs 19.41 pg/mL; P = .005). There was an increased odds of MTCT for every log2 increase in maternal sCD14 concentration, after adjustment for maternal HIV load, CD4 count and cART exposure (adjusted odds ratio, 3.51; 95% confidence interval, 1.21-10.21). Maternal monocyte activation may adversely influence the risk of MTCT of HIV.

J Infect Dis. 2016 Mar 1;213(5):762-5. doi: 10.1093/infdis/jiv479. Epub 2015 Oct 6. PMID: 26443598 

Categories

CRS
Topics

Clinical Trials

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More